Cancer Institute;
Chinese Academy of Medical Sciences;
Beijing;
Cancer Institute;
Chinese Academy of Medical Sciences;
Beijinghis paper described T cell proliferative response by an alternative pathway in normal subjects and In patients with malignant diseases. Two McAbs;
Anti-CCTl and Lo-CD2-act recognizing two distinct epitopes on E-receptor (CD2) were used to costimulate PBMC. Proliferative responsiveness was measured by 3H-thymidine incorporation. It was found that 82% of 72 nonnal subjects gave proliferative response whereas only 23% of the 93 patients did. The average cpm±SD in patients with bladder cancer (118±2314);
kidney cancer (1619±2719) or lymphoma (2518±4057) was significantly lower than that in normal subjects (4935±2314);
(P<0.001). These results indicate that T cell proliferation through the alternative pathway was significantly depressed in patients with cancer;
and this can be used as a new parameter to monitor the immune status of cancer patients.;
proliferative; bladder; thymidine; CELL; incorporation; depressed; secretion; monitor; monoclonal; donor;